{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:02:28Z","timestamp":1793088148727,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint criteria for methicillin-susceptible\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MSSA) treatment with ceftriaxone are based upon high dose (4\u00a0g\/day) rather than standard dose (2\u00a0g\/day) posology. This is particularly relevant for invasive infections, and for patients managed via Outpatient Parenteral Antimicrobial Therapy (OPAT), but may result in increased drug toxicity. We quantified the incidence of neutropenia, thrombocytopenia and raised liver enzymes between standard and high dose ceftriaxone in adult patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Adult outpatients prescribed\u2009\u2265\u20097\u00a0days of ceftriaxone therapy were identified, and clinical, pharmacological, and laboratory parameters extracted from electronic health records between May 2021 and December 2021. Incidence and median time to haematological and hepto-toxicity were analysed. Univariate odds ratios were calculated for neutrophil count and ALT levels with 95% confidence level and Chi squared\/Fisher\u2019s exact test used to identify statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Incidence of neutropenia was comparable between both groups; 8\/47 (17%) in the 2\u00a0g group vs 6\/39 (15.4%) in the 4\u00a0g group (OR 0.89 (95% CI 0.26\u20132.63), p\u2009&gt;\u20090.999). Median time to neutropenia was 12 and 17\u00a0days in the 2\u00a0g and 4\u00a0g groups respectively. Thrombocytopenia was observed in 0\/47 in the 2\u00a0g group compared with 3\/39 (7.7%) in the 4\u00a0g group (p 0.089). Median time to thrombocytopenia was 7\u00a0days in the 4\u00a0g group. Elevated liver enzymes did not clearly correlate with ceftriaxone dosing; present in 5\/47 (10.6%) and 2\/39 (5.1%) for 2\u00a0g and 4\u00a0g respectively (OR 0.45 (95% CI 0.87\u20132.36), p 0.448). Treatment cessation due to any adverse effect was similar between both groups 2\/47 (4.3%) for 2\u00a0g and 3\/39 (7.7%) for 4\u00a0g (OR 1.86 (95% CI 0.36\u201310.92), p 0.655).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Increased adverse effects with 4\u00a0g (over 2\u00a0g) daily dosing of ceftriaxone was not observed in an OPAT population. However absolute development of haematological and liver dyscrasias was appreciable\u2014monitoring of liver function and full blood count in patients receiving prolonged ceftriaxone is indicated irrespective of dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-022-07925-y","type":"journal-article","created":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T02:02:36Z","timestamp":1671847356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Haematological and hepatic adverse effects of ceftriaxone in ambulatory care: a dual-centre retrospective observational analysis of standard vs high dose"],"prefix":"10.1186","volume":"22","author":[{"given":"Rakhee","family":"Mistry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Troise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeela","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke S. P.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,24]]},"reference":[{"issue":"9","key":"7925_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2165\/00003088-200140090-00004","volume":"40","author":"TR Perry","year":"2001","unstructured":"Perry TR, Schentag JJ. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet. 2001;40(9):685\u201394. https:\/\/doi.org\/10.2165\/00003088-200140090-00004.","journal-title":"Clin Pharmacokinet"},{"key":"7925_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12016-013-8367-x","volume":"45","author":"SD Dickson","year":"2013","unstructured":"Dickson SD, Salazar KC. Diagnosis and management of immediate hypersensitivity reactions to cephalosporins. Clin Rev Allerg Immunol. 2013;45:131\u201342. https:\/\/doi.org\/10.1007\/s12016-013-8367-x.","journal-title":"Clin Rev Allerg Immunol"},{"issue":"7","key":"7925_CR3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2165\/00003495-200262070-00005","volume":"62","author":"HM Lamb","year":"2002","unstructured":"Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs. 2002;62(7):1041\u201389. https:\/\/doi.org\/10.2165\/00003495-200262070-00005.","journal-title":"Drugs"},{"key":"7925_CR4","unstructured":"Roche Products Limited. Summary of product characteristics: Rocephin 2g powder for solution for injection or infusion. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/7932\/smpc. Accessed 14 March 2022."},{"key":"7925_CR5","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2022. Breakpoint tables for interpretations of MICs and zone diameters. 2022. https:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 14 Mar 2022."},{"issue":"3","key":"7925_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations and management. Clin Microbiol Rev. 2015;28(3):603\u201361. https:\/\/doi.org\/10.1128\/CMR.00134-14.","journal-title":"Clin Microbiol Rev"},{"key":"7925_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11096-012-9637-z","volume":"34","author":"CJA Duncan","year":"2012","unstructured":"Duncan CJA, Barr DA, Seaton RA. Outpatient parenteral antimicrobial therapy, a review. Int J Clin Pharm. 2012;34:410\u20137. https:\/\/doi.org\/10.1007\/s11096-012-9637-z.","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"7925_CR8","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/jac\/dkq339","volume":"65","author":"CJA Duncan","year":"2010","unstructured":"Duncan CJA, Evans TJ, Seaton RA. Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2010;65(11):2483\u20134. https:\/\/doi.org\/10.1093\/jac\/dkq339.","journal-title":"J Antimicrob Chemother"},{"key":"7925_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00228-016-2064-7","volume":"72","author":"K Nakaharai","year":"2016","unstructured":"Nakaharai K, Sakamoto Y, Yaita K, Yoshimura Y, Igarashi D, Tachikawa N. Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score. Eur J Clin Pharmacol. 2016;72:1003\u201311. https:\/\/doi.org\/10.1007\/s00228-016-2064-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"7925_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cmi.2021.10.022","volume":"28","author":"J Curran","year":"2022","unstructured":"Curran J, Lo J, Leung V, Brown K, Schwartz KL, Daneman N, Garber G, Wu JHC, Langford BJ. Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis. Clin Microbiol Infect. 2022;28(4):479\u201390. https:\/\/doi.org\/10.1016\/j.cmi.2021.10.022.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07925-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07925-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07925-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T09:11:55Z","timestamp":1672218715000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07925-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,24]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7925"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07925-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,24]]},"assertion":[{"value":"2 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was registered as a service evaluation (reference number: CSS094) on 19th April 2022 with the Chelsea & Westminster NHS Foundation Trust Clinical Governance Committee. Additional ethical review was not required for this study as per the Committee. The need for individual patient written informed consent was waived for this retrospective cohort study by the Chelsea & Westminster NHS Foundation Trust Clinical Governance Committee. All data collected was stored in concordance with Data Protection Act 2018 and General Data Protection Regulation. All procedures were performed in accordance with relevant guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No data necessitating consent was used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LSPM has consulted for\/received speaker fees from bioMerieux (2013\u20132022), Eumedica (2016\u201322) DNAelectronics (2015\u20132018), Dairy Crest (2017\u20132018), Profile Pharma (2018), Umovis Labs (2020\u20132021), Kent Pharma (2021), Shionogi (2021\u20132022), Pulmocide (2021), Sumitovant (2021\u20132022), and Pfizer (2018\u20132022), and received research grants from the National Institute for Health Research (2013\u20132022), Leo Pharma (2016), LifeArc (2020\u20132022), and CW\u2009+\u2009Charity (2018\u20132022). NM has consulted for Pfizer (2019\u20132022) and received educational support from Eumedica (2015) and Baxter (2017). SH has consulted for\/received speaker fees Shionogi (2021\u201322), BowMed (2021), Eumedica (2020), Kent Pharma (2021), Gilead (2021\u201322), Tillots (2022), Baxter (2022) and Pfizer (2020\u20132022) and received research grants from the CW\u2009+\u2009Charity (2021\u20132022). All other authors have no conflicts of interest to declare<b>.<\/b>","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"959"}}